Latest Conference Articles

In this interview, Dr. Bhatia described the main takeaways from his conference presentation titled ‘JAKs and TYKs - What you Need to Know.’

The cross-specialty collaboration between dermatologists and these fields has been a daily occurrence, as inflammation-targeting drugs and comorbid patients have brought team closer together.

During the next part of his Q&A interview, Dr. Lebwohl further described new and future research into treating psoriasis.

Since roflumilast cream was approved by the FDA last July, one dermatology physician assistant advocates for its use as a primary medication.

This Q&A interview with Dr. Lebwohl featured a discussion about which therapies may be the best for patients who have psoriasis.

The introduction of the TYK2 inhibitor is the latest advancement toward cross-specialty care with systemic agents.

Ahead of Fall Clinical Dermatology 2023 Conference for PAs & NPs, Glick discusses how the COVID-19 reshaped dermatology roles, and the value of physician assistants and nurse practitioners in the current care team.

Dr. Del Rosso spoke regarding his conference presentation, titled ‘What’s New in the Medicine Chest,’ in which he describes newer therapies in the dermatology field.

In recent years, the field of endophenotyping has garnered significant attention in sleep health, signaling a growing recognition of the need to move beyond simplistic measures.

Patients participating in the open-label extension trial had a few months for titration, more than 24 months for stable dosing, and a one-week follow up.

“How can we use these data to harness the power it has to do a better job of predicting clinical outcomes and looking at treatment responsiveness?” Dr. Reena Mehra asks.

CCDC3 has shown to repress inflammatory activity of TNF-alpha, a cytokine postulated involved in sleep regulation and MARCHF1 has shown to inhibit cellular insulin sensitivity and promotes NF-KB, with degree of activation positively correlating with OSA severity.

The goal is to address the desaturation drop in oxygen as well as well as treating the arousal effect in the brain, Dr. Lambarca Trocios says.

Sleep fragmentation in obstructive sleep apnea is measured by the number of EEG arousals per hour of sleep but new data from SLEEP 2023 dive deeper into the intensity of arousals.

The results of the study presented at SLEEP 2023 were statistically significant, but not clinically meaningful.

There is a need for more large scale studies focusing on treatment adherence for sleep apnea in minority communities.

The higher severity of obstructive sleep apnea is associated with an increased risk of dementia, according to data from SLEEP 2023.

Young adults with psychiatric and behavioral disorders are more likely to experience a decline in sleep intensity and sleep depth more dramatically after adolescence.

Pediatric sleep conditions remain understudied.

With a high rate of lost patients, effective treatment is compromised regardless of the success rendered by unattended portable sleep studies, investigators explain.

Risk factors for trouble sleeping identified, including female sex, former smoking, and diabetes, obstructive lung disease, daytime sleepiness, insomnia, nocturia, and/or snorting/gasping/breathing cessation during sleep.

The changes in sleep quality were notably associated with a higher prevalence of obesity indicators in men following the COVID-19 outbreak.

Experiencing everyday discrimination is a significant predictor of sleep-related impairments among Black adults, highlighting the detrimental impact of discrimination.

The results show intraindividual variability in total sleep time, time in bed, midpoint sleep, bedtime, and risetime were associated with lower sleep quality.

“Our findings underline the importance of sleep health in treating depression as the nation battles the current mental health crisis,” investigators write.

A preference for eveningness was significantly associated with worse overall sleep difficulties, longer sleep latency, reduced sleep satisfaction, more prolonged sleep inertia, more daytime naps, and more severe depressive symptomatology.

“These results have significant implications for the scalability of circadian medicine, particularly as consumer-based wearable technology is already commonplace,” investigators explain.

Higher levels of hydrocinnamate and indolepropionate were associated with lower WHIIRS, with stronger associations found in female participants.